Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nanologica AB ( (SE:NICA) ) just unveiled an announcement.
Nanologica’s board has approved a package of capital measures comprising two directed share issues totaling approximately SEK 13.7 million and a fully secured rights issue of about SEK 82.5 million, all at a subscription price of SEK 0.40 per share, subject to approval at an extraordinary general meeting on 4 March 2026. The directed set-off issue to Ardena Sweden AB settles part of the purchase price for the acquisition of Ardena Södertälje AB, while a second directed issue brings in new investors, including Exmere Ltd and CEO Andreas Bhagwani, and the rights issue—backed 100% by subscription and underwriting commitments, with main owner Flerie Invest AB taking a dominant role and converting loans—aims to strengthen Nanologica’s balance sheet and secure working capital for scaling production and sales of its NLAB Saga® silica media, while also reducing debt through set-offs and potential additional directed issues to lenders and underwriters.
The most recent analyst rating on (SE:NICA) stock is a Sell with a SEK0.51 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.
More about Nanologica AB
Nanologica AB is a Swedish life science company focused on advanced silica-based materials, including its NLAB Saga® silica media, used in pharmaceutical production and chromatographic applications. The company targets global pharma and biotech customers, positioning itself within the high-value drug development and manufacturing supply chain.
Average Trading Volume: 168,106
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK50.19M
Find detailed analytics on NICA stock on TipRanks’ Stock Analysis page.